Roche (OTCMKTS:RHHBY) Upgraded by Morgan Stanley to Equal Weight Rating

Key Points

• Morgan Stanley upgraded Roche from "underweight" to "equal weight" and set a $46 price objective, which implies roughly a 9.8% downside from the company's current price.
• Across brokerages, analysts are split with five "Buy" and six "Hold" ratings; the consensus is an average rating of "Hold" and an average target price of $51.50.
• RHHBY traded at $51.01 on Friday (down $0.85), with a 50‑day moving average of $52.94, a 200‑day moving average of $50.64, and a 52‑week range of $35.07–$60.85.

Roche (OTCMKTS:RHHBY - Get Free Report) was upgraded by stock analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating in a note issued to investors on Friday, MarketBeat.com reports. The firm presently has a $46.00 price objective on the stock. Morgan Stanley's price target suggests a potential downside of 9.82% from the company's current price.

Several other brokerages have also commented on RHHBY. Zacks Research raised Roche from a "strong sell" rating to a "hold" rating in a research note on Monday, January 5th. Citigroup started coverage on Roche in a research note on Tuesday, January 27th. They issued a "buy" rating on the stock. The Goldman Sachs Group raised Roche from a "sell" rating to a "hold" rating in a research note on Thursday, January 15th. Argus raised Roche from a "hold" rating to a "buy" rating in a research note on Monday, April 6th. Finally, TD Cowen reiterated a "hold" rating on shares of Roche in a research report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $51.50.

Roche Price Performance

RHHBY stock traded down $0.85 during trading on Friday, hitting $51.01. The company had a trading volume of 86,931 shares, compared to its average volume of 2,599,239. The company has a fifty day moving average price of $52.94 and a two-hundred day moving average price of $50.64. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. Roche has a fifty-two week low of $35.07 and a fifty-two week high of $60.85.

Hedge Funds Weigh In On Roche

Several institutional investors have recently bought and sold shares of RHHBY. Bard Financial Services Inc. raised its position in Roche by 1.3% in the 3rd quarter. Bard Financial Services Inc. now owns 138,650 shares of the company's stock valued at $5,797,000 after purchasing an additional 1,800 shares during the last quarter. Diversified Trust Co raised its position in Roche by 0.5% in the 3rd quarter. Diversified Trust Co now owns 57,881 shares of the company's stock valued at $2,363,000 after purchasing an additional 310 shares during the last quarter. Salomon & Ludwin LLC raised its position in Roche by 256.6% in the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company's stock valued at $129,000 after purchasing an additional 2,053 shares during the last quarter. Canopy Partners LLC raised its position in shares of Roche by 4.9% during the third quarter. Canopy Partners LLC now owns 7,580 shares of the company's stock worth $317,000 after acquiring an additional 352 shares during the last quarter. Finally, Boston Common Asset Management LLC raised its position in shares of Roche by 1.9% during the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company's stock worth $15,049,000 after acquiring an additional 6,720 shares during the last quarter.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.